Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have earned a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $17.13.

A number of research firms recently issued reports on FOLD. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Bank of America lifted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. reduced their target price on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 target price on shares of Amicus Therapeutics in a research note on Friday, September 20th. Finally, Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price for the company.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $11.74 on Friday. Amicus Therapeutics has a 52-week low of $9.02 and a 52-week high of $14.57. The company has a 50-day simple moving average of $11.14 and a 200 day simple moving average of $10.59. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The company has a market capitalization of $3.48 billion, a PE ratio of -30.10 and a beta of 0.68.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The business had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. During the same quarter last year, the company posted ($0.15) earnings per share. The firm’s quarterly revenue was up 34.0% compared to the same quarter last year. On average, research analysts predict that Amicus Therapeutics will post -0.06 EPS for the current year.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $10,382,718.34. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 22,500 shares of company stock worth $253,275 over the last three months. 2.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Amicus Therapeutics

Hedge funds have recently made changes to their positions in the business. Assenagon Asset Management S.A. bought a new stake in shares of Amicus Therapeutics in the 2nd quarter worth approximately $8,386,000. M&G Plc lifted its holdings in shares of Amicus Therapeutics by 12.4% in the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares during the last quarter. Edgestream Partners L.P. lifted its holdings in shares of Amicus Therapeutics by 1,290.4% in the 1st quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock worth $3,183,000 after acquiring an additional 250,734 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Amicus Therapeutics by 7.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock worth $1,183,000 after acquiring an additional 7,304 shares during the last quarter. Finally, Fiera Capital Corp lifted its holdings in shares of Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after acquiring an additional 58,113 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.